Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 6/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836103 | 1.00 | MAPT (0.39) | MAPTALOX15TSHRACAT1CXCR4 | |
| SCHEMBL25836237 | 0.95 | TSHR (0.39) | MAPTALOX15TSHRACAT1CXCR4 | |
| SCHEMBL26032102 | 0.94 | MAPT (0.38) | MAPTALOX15TSHRCNR1CNR2 | |
| SCHEMBL26033614 | 0.94 | MAPT (0.38) | MAPTALOX15TSHRCNR1CNR2 | |
| SCHEMBL25836356 | 0.89 | MAPT (0.37) | MAPTALOX15TSHRCNR1CNR2 | |
| SCHEMBL26036063 | 0.84 | MAPT (0.37) | MAPTALOX15TSHRACAT1CXCR4 | |
| SCHEMBL24340752 | 0.84 | MAPT (0.44) | MAPTALOX15TSHRCXCR4RXFP1 | |
| SCHEMBL26032106 | 0.83 | CNR2 (0.40) | MAPTALOX15TSHRCNR1CNR2 | |
| SCHEMBL24340753 | 0.83 | MAPT (0.43) | MAPTALOX15TSHRCXCR4RXFP1 | |
| SCHEMBL24340634 | 0.82 | HPGD (0.48) | MAPTALOX15TSHRCXCR4RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MAPT 3973/4885ALOX15 1471/4885TSHR 1324/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MAPT 4094/4885ALOX15 4619/4885TSHR 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.